Igm Biosciences Inc. (IGMS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
IGMS Chart
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of a loss of $0.3 per share. This compares to a loss of $0.79 per share a year ago.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.83 per share a year ago.
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Igm Biosciences Inc. (IGMS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Igm Biosciences Inc. Profile
| - Industry | - Sector | Mary Beth Harler CEO | NASDAQ (NGS) Exchange | 449585108 CUSIP |
| US Country | 149 Employees | - Last Dividend | - Last Split | 18 Sep 2019 IPO Date |
Overview
IGM Biosciences, Inc. is a pioneering clinical-stage biotechnology entity that is at the forefront of developing novel Immunoglobulin M (IgM) antibodies aimed at combating various cancers, as well as autoimmune and inflammatory diseases. Born from the roots of Palingen, Inc., the company underwent a significant rebranding to IGM Biosciences, Inc. in 2010, signifying a new era in its pursuit of medical innovations. Since its inception in 1993 and nestled in the technological hub of Mountain View, California, IGM Biosciences has been steadfast in its mission to revolutionize the treatment landscape of debilitating diseases. Distinguished by its collaboration and license agreement with Genzyme Corporation, IGM Biosciences showcases its commitment to advancing the field of IgM antibodies through innovative research and development efforts.
Products and Services
- Aplitabart
- Imvotamab
- IGM-2644
A novel Death Receptor 5 Agonist IgM antibody, Aplitabart is at the cutting-edge of IGM Biosciences' oncological efforts, specifically targeting colorectal cancer. This pioneering antibody exemplifies the company’s dedication to exploring and expanding the therapeutic potentials of IgM antibodies in oncology.
Imvotamab stands as a testament to the versatile therapeutic applications of IgM antibodies, being a CD20 x CD3 bispecific IgM antibody. Currently in Phase Ib clinical trials, imvotamab is being assessed for its efficacy in treating myositis, systemic lupus erythematosus, and rheumatoid arthritis. This reflects IGM Biosciences' relentless pursuit of innovative treatments for autoimmune diseases.
IGM-2644 is a bispecific T cell engaging IgM antibody that targets both CD38 and CD3 proteins. This dual-targeting approach holds promise for the treatment of autoimmune diseases, showcasing IGM Biosciences’ commitment to leveraging the therapeutic potential of IgM antibodies in autoimmune disease management.
